“Today’s unanimous ODAC vote – 12-0 in favor – is a milestone for the field of multiple myeloma,” said Dr. C. Ola Landgren, director of Sylvester’s Myeloma Research Institute. “It will also set the stage for the development of novel therapies for other cancers.”